NCT02494258 2025-05-22A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological DisordersCelgenePhase 2 Completed5 enrolled
NCT04578600 2025-04-24CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaUniversity of California, DavisPhase 1 Completed8 enrolled
NCT03493646 2024-05-28Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486Kirby InstitutePhase 2 Completed40 enrolled
NCT02223052 2020-05-12Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCelgenePhase 1 Completed89 enrolled
NCT01835587 2018-11-20Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).CelgenePhase 1/2 Completed31 enrolled 30 charts